Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Thomas Jefferson University
Thomas Jefferson University
City of Hope Medical Center
Eastern Cooperative Oncology Group
City of Hope Medical Center
University of Nebraska
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Roswell Park Cancer Institute
Children's Oncology Group
Roswell Park Cancer Institute
Wake Forest University Health Sciences
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Zimmer Biomet
University of Wisconsin, Madison
Roswell Park Cancer Institute
Roswell Park Cancer Institute
University of Chicago
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
Case Comprehensive Cancer Center
Stanford University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
University of Washington
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
Massachusetts General Hospital
Fred Hutchinson Cancer Center